Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles

被引:18
作者
Barghi, Leila [1 ,2 ]
Asgari, Davoud [1 ]
Barar, Jaleh [1 ,3 ]
Nakhlband, Aylar [3 ]
Valizadeh, Hadi [1 ]
机构
[1] Tabriz Univ Med Sci, Fac Pharm, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
关键词
Erlotinib; PCEC; solvent displacement method; nanoparticles; SHELL TYPE NANOPARTICLES; DRUG-RELEASE BEHAVIORS; CELL LUNG-CANCER; BIODEGRADABLE POLYMERS; TRIBLOCK COPOLYMER; TARGETED DELIVERY; MICROSPHERES; NANOSPHERES; POLY(EPSILON-CAPROLACTONE); PACLITAXEL;
D O I
10.7314/APJCP.2014.15.23.10281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Development of a nanosized polymeric delivery system for erlotinib was the main objective of this research. Materials and Methods: Poly caprolactone-polyethylene glycol-polycaprolactone (PCEC) copolymers with different compositions were synthesized via ring opening polymerization. Formation of triblock copolymers was confirmed by HNMR as well as FT-IR. Erlotinib loaded nanoparticles were prepared by means of synthesized copolymers with solvent displacement method. Results: Physicochemical properties of obtained polymeric nanoparticles were dependent on composition of used copolymers. Size of particles was decreased with decreasing the PCL/PEG molar ratio in used copolymers. Encapsulation efficiency of prepared formulations was declined by decreasing their particle size. Drug release behavior from the prepared nanoparticles exhibited a sustained pattern without a burst release. From the release profiles, it can be found that erlotinib release rate from polymeric nanoparticles is decreased by increase of CL/PEG molar ratio of prepared block copolymers. Based on MTT assay results, cell growth inhibition of erlotinib has a dose and time dependent pattern. After 72 hours of exposure, the 50% inhibitory concentration (IC50) of erlotinib hydrochloride was appeared to be 14.8 mu M. Conclusions: From the obtained results, it can be concluded that the prepared PCEC nanoparticles in this study might have the potential to be considered as delivery system for erlotinib.
引用
收藏
页码:10281 / 10287
页数:7
相关论文
共 48 条
  • [1] Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status
    Aydiner, Adnan
    Yildiz, Ibrahim
    Seyidova, Avesta
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (05) : 3255 - 3261
  • [2] Modified Synthesis of Erlotinib Hydrochloride
    Barghi, Leila
    Aghanejad, Ayuob
    Valizadeh, Hadi
    Barar, Jaleh
    Asgari, Davoud
    [J]. ADVANCED PHARMACEUTICAL BULLETIN, 2012, 2 (01) : 119 - 122
  • [3] Synthesis and thermal properties of poly(ethylene glycol)-poly(ε-caprolactone) copolymers
    Bogdanov, B
    Vidts, A
    Van Den Bulcke, A
    Verbeeck, R
    Schacht, E
    [J]. POLYMER, 1998, 39 (8-9) : 1631 - 1636
  • [4] Bolandnazar S, 2013, ADV PHARM B, V19, P22
  • [5] Clay D, 2005, P T, V30, P561
  • [6] Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog
    Dubey, Nazneen
    Varshney, Raunak
    Shukla, Jaya
    Ganeshpurkar, Aditya
    Hazari, Puja P.
    Bandopadhaya, Guru P.
    Mishra, Anil K.
    Trivedi, Piyush
    [J]. DRUG DELIVERY, 2012, 19 (03) : 132 - 142
  • [7] Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity
    Fonseca, C
    Simoes, S
    Gaspar, R
    [J]. JOURNAL OF CONTROLLED RELEASE, 2002, 83 (02) : 273 - 286
  • [8] Polymer microspheres for controlled drug release
    Freiberg, S
    Zhu, X
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 282 (1-2) : 1 - 18
  • [9] Gale Danielle M, 2003, Semin Oncol Nurs, V19, P193, DOI 10.1016/S0749-2081(03)00047-0
  • [10] Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods
    Galindo-Rodriguez, S
    Allémann, E
    Fessi, H
    Doelker, E
    [J]. PHARMACEUTICAL RESEARCH, 2004, 21 (08) : 1428 - 1439